Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Selection of Lactobacillus Strains for Urogenital Probiotic Applications

Reid, Gregor, Bruce, Andrew W.·2001·The Journal of Infectious Diseases

Abstract

Almost 20 years ago, it was shown that lactobacilli expressed properties that appeared to play a role in protecting the host from urogenital infection [1]. Since then, studies have shown that exogenously applied lactobacilli or indigenous lactobacilli, can reduce the risk of urinary tract infection (UTI) [2–4]. The investigations have focused upon the large clinical problem of lactobacilli depletion being associated with UTI, bacterial vaginosis (BV), and yeast vaginitis, which together cause an estimated one billion episodes of disease among women each year The application of exogenous organisms, such as lactobacilli, to the host is termed probiotics, which is broadly defined as a living microorganism administered to promote the health of the host by treating or preventing disease. While many so-called probiotic products are available, the content and viability of most are unreliable [5, 6], leading to use of strains that do not colonize and therefore do not protect against recurrent UTI [7]. For probiotic applications to the urogenital tract to be successful, it is critical that a scientific basis be established for selection of strains. This should at least shed some light upon their mechanism of action in vivo. Several properties appear to be critical, namely the ability to colonize the host, to inhibit pathogen binding and growth, and to create a balanced flora that resists spermicidal killing [8–10] Selection of Lactobacillus strainsAn analysis of the scientific and dairy literature showed that around 7 strains had sufficiently substantial data published on their properties that are required of an antipathogen probiotic [8]. These Lactobacillus strains are L. rhamnosus GG, L. acidophilus NCFM, L. casei Shirota, L. reuteri MM53, L. casei CRL-431, L. rhamnosus GR-1, and L. fermentum RC-14. Other Lactobacillus strains, such as L. johnsonii LC1, appear capable of stimulating the intestinal immune response, and L. plantarum 299V may have some beneficial properties, but neither appear yet in extensive peer-reviewed publications The fact that not all lactobacilli possess properties that are required to colonize the vagina and inhibit urogenital pathogens needs to be emphasized. Until now, no studies comparing commercial strains have been done. Using methodologies published previously for adhesion [11], biosurfactant production [12], and hydrogen peroxide production [13], 7 commercial strains were found to lack at least one of the important properties required of a urogenital probiotic: L. rhamnosus GG (Valio), L. acidophilus NCFM (Rhodia), L. casei Shirota (Yakult), L. casei DN-114 001 (Actimel), L. acidophilus SIDU (SIDU Enterprises), L. johnsonii LJ1 (Nestle), and L. plantarum 299V (Probi) (table 1). These strains have been selected for intestinal activity, and clearly that is the environment to which they should be used unless substantial scientific evidence for other applications is produced Major deficiencies in commercial probiotic organisms with respect to their selection for colonizing the urogenital tract and preventing bladder and vaginal infection Three Lactobacillus strains have emerged with excellent clinical potential for the urogenital tract: L. crispatus CTV05, L. rhamnosus GR-1, and L. fermentum RC-14 [8]. Of these, little is known about L. crispatus CTV05’s properties other than its ability to colonize the vagina and to produce hydrogen peroxide in vitro. This strain is being tested to prevent recurrence of BV, and while early data are promising, full clinical results will not be available for about 2 years The other 2 strains possess properties that make them potentially excellent candidates for the clinical treatment of the urogenital tract and the intestine. L. rhamnosus GR-1 is highly adherent to uroepithelial and vaginal cells, resistant to spermicide, able to inhibit growth and adhesion of urogenital and intestinal pathogens, and able to colonize the vagina [8, 14] and intestine [14a]. L. fermentum RC-14 is an adherent strain that produces hydrogen peroxide and a highly potent biosurfactant, and it also colonizes the vagina and the intestine [8, 14a]. An important component of L. fermentum RC-14’s anti-infective capacity is its biosurfactant, which inhibits adhesion of a range of uropathogens, including Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Pseudomonas aeruginosa Group B streptococci, Providencia stuartii and Staphylococcus epidermidis and the genital pathogens Candida albicans and Gardnerella vaginalis Several collagen-binding proteins have been isolated by surface-enhanced laser desorption/ionization studies (figure 1) [15]. Of particular interest is a 29-kDa protein that not only binds lactobacilli to collagen on vaginal epithelial cells but also inhibits significant numbers of pathogens from binding to surfaces [16]. Of note, another probiotic organism, L. casei Shirota, which is ingested by an estimated 24 million people each day, lacks this 29-kDa prote

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/318841

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 159

Metadata

Authors
Reid, G., & Bruce, A. W.
Venue
The Journal of Infectious Diseases
Published
2001-03
Volume
183
Issue
s1
Pages
S77-S80
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2126565395
Cited by
159
References
3
FWCI
17.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.